Healthcare
Medartis Holding AG(MDRSF)
Live Price
Offline$115.00
+0.00% today
1Y Change
+72.47%
Window
Jun 25, 2025 → Jun 23, 2026
- Market Cap
- $960.00M
- Revenue Growth
- +19.8%
- EPS Growth
- +157.7%
- Dividend Yield
- 0.0%
Coverage: 250 bars · Jun 25, 2025 → Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Medartis Holding AG (MDRSF) is a Healthcare stock with a market cap of $960.00M and listed on OTC. The stock last traded around $115.00 and up 72.5% across the available one-year price window (Jun 25, 2025 → Jun 23, 2026). Baseline metrics include revenue growth of +19.8%, EPS growth of +157.7%, a dividend yield of 0.0%. What stands out right now is revenue +19.8%, EPS +157.7%, free cash flow -55.5% with operating margin 0.4% and ROIC 0.2%. Valuation already assumes a fairly strong business story at P/E 114.5 and price/sales 3.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines MDRSF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+19.8% vs +7.6% peer median
Operating Margin
Below sector median
+0.4% vs +19.4% peer median
P/E
Above sector median
114.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +19.8% and EPS at +157.7%, with operating margin around 0.4%.
Benchmark Edge
MDRSF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MDRSF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MDRSF Max Drawdown
-34.63%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MDRSF and SPY.
Company Overview
Medartis Holding AG
Other OTC
Medartis Holding AG, a medical device company, develops, manufactures, and sells implant solutions worldwide. Its medical devices are used for the treatment of surgical fixation of bone fractures for upper and lower extremities, as well as for the cranio-maxillofacial surgery. The company offers osteosynthesis instruments for the areas of the hand, wrist, elbow, shoulder, and foot and ankle, as well as for the areas of the mandible, midface, orthognathic, and cranium under the APTUS and MODUS names. The company serves the surgeons, hospitals, and medical centers, as well as group purchasing organizations. Medartis Holding AG was founded in 1997 and is headquartered in Basel, Switzerland.
- Leadership
- Matthias Schupp
- IPO Date
- Jan 17, 2020
- Employees
- 816
- Street Address
- Hochbergerstrasse 60E
- Mailing
- Basel, 4057
- Region
- Basel, CH
- Reporting Currency
- USD
- Investor Line
- 41 61 633 34 34
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 114.5
- EV/EBITDA
- 42.2
- Price/Sales
- 3.6
- Price/Book
- 3.5
Growth
- Revenue
- +19.8%
- EPS
- +157.7%
- Free Cash Flow
- -55.5%
Profitability
- Gross Margin
- 75.9%
- Operating Margin
- 0.4%
- Net Margin
- 3.1%
- ROE
- 3.1%
- ROIC
- 0.2%
Balance Sheet
- Debt/Equity
- 0.57
- Current Ratio
- 2.21
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.